GNS and the Global Alzheimer's Platform Foundation Partner to advance Alzheimer's R&D - GNS

Somerville, MA, June 1st, 2022: GNS, the leader in the use of "Virtual Patients," Causal AI and simulation technology for biopharmaceutical drug discovery and development, and the Global Alzheimer's Platform Foundation (GAP) today announced a 3-year partnership. This innovative partnership will leverage the fully de-identified dataset of rich clinico-genomic data from GAP's Bio-Hermes study to build the next generation Gemini Virtual Patient in Alzheimer's Disease (AD). The data from the groundbreaking Bio-Hermes study includes samples from more than 1,000 volunteer participants. This is the first Alzheimer's platform study to prioritize diversity in the study protocol. It is the largest AD trial of its kind evaluating biomarkers, surrogate markers, and cognitive tests.